Over the last two decades, there have been significant investments designed to advance clinical and translational research (CTR) with an emphasis on supporting early career investigators and building a cadre of skilled researchers. Despite the investments, there are no comprehensive measurement tools to track individual-level progress along the research continuum as supports are put in place.

The Researcher Investment Tool (RIT) is a novel tool that was created to provide a consistent approach for measuring individual-level changes in the research career trajectory of investigators receiving support from CTR programs.

The RIT is a 90-item questionnaire, with eight domains and four sub-domains, designed to measure a researcher’s experiences and perceptions. Several rounds of testing were conducted to assess the tool’s face and content validity as well as the internal consistency and test-retest reliability.

Psychometric testing revealed strong content validity and good internal consistency with Cronbach’s alpha coefficients ranging from 0.85 to 0.97 across all domains. Test-retest reliability results also revealed stability in the domain measures over time with Pearson’s correlation coefficients ranging from 0.70 to 0.98 for all but one domain (.53).

This novel RIT may be useful to evaluators when measuring the impact of investments designed to support early career clinical and translational researchers.

Parent depression is a well-established prospective risk factor for adverse offspring mental health. Multiple lines of evidence suggest that improvements in parent depression predicts improved offspring mental health. However, no systematic review has examined the impact on offspring of psychological treatment of purely parent depression after the postnatal period.

To systematically review the literature of randomised controlled trials examining the impact on offspring mental health outcomes of psychological interventions for parental depression after the postnatal period.

We pre-registered our systematic review on PROSPERO (CRD42023408953), and searched the METAPSY database in April 2023 and October 2024, for randomised controlled trials of psychological interventions for adults with depression, which also included a child mental health or wellbeing outcome. We double screened 938 studies for inclusion using the ‘Paper in a Day’ approach. All included studies would be rated using the Cochrane Risk of Bias tool.

We found no studies that met our inclusion criteria.

Robust research into psychological therapy for depression in adults outside the postnatal period has failed to consider the potential benefits for the children of those adults. This is a missed clinical opportunity to evaluate the potential preventive benefits for those children at risk of adverse psychological outcomes, and a missed scientific opportunity to test mechanisms of intergenerational transmission of risk for psychopathology. Seizing the clinical and scientific opportunities would require adult-focused mental health researchers to make inexpensive additions of child mental health outcomes measures to their evaluation projects.

Vancomycin-resistant enterococci (VRE) can cause serious healthcare-associated infections. Patients can become colonized and infected through contact with healthcare workers, hospital surfaces, equipment, and other patients. We evaluated the utility of broadly applied whole-genome sequencing (WGS) surveillance of vancomycin-resistant Enterococcus faecium (VREfm) for detection of hospital-based transmission.

Retrospective genomic and epidemiologic analysis of clinical VREfm isolates

Brigham and Women’s Hospital, an 800-bed tertiary care center in Boston, MA, USA

VREfm was isolated from patient screening and diagnostic specimens. We sequenced the genomes of 156 VREfm isolates, 12 at the request of infection control and 144 as a convenience sample, and used single nucleotide polymorphism (SNP) differences to assess relatedness. For isolate pairs separated by 15 or fewer SNPs by two orthogonal comparison methods, we mapped epidemiologic connections to identify putative transmission clusters.

We found evidence for 16 putative transmission clusters comprising between two and four isolates each and involving 41/156 isolates (26.3%). Our analysis discovered 14 clusters that were missed by traditional surveillance methods and additional members of two clusters that were detected by traditional methods. Patients in four transmission clusters were linked only by exposure to the postanesthesia care unit.

We show that WGS surveillance for VREfm can support infection control investigations and detect transmission events missed by routine surveillance methods. We identify the postanesthesia care unit as a locus for VREfm transmission, which demonstrates how WGS surveillance could inform targeted interventions to prevent the spread of VREfm.

We compared the Institute for Clinical and Economic Review’s (ICER) ratings of comparative clinical effectiveness with the German Federal Joint Committee’s (G-BA) added benefit ratings, and explored what factors, including the evidence base, may explain disagreement between the two organizations.

Drugs were included if they were assessed by ICER under its 2020–2023 Value Assessment Framework and had a corresponding assessment by G-BA as of March 2023 for the same indication, patient population, and comparator drug. To compare assessments, we modified ICER’s proposed crosswalk between G-BA and ICER benefit ratings to account for G-BA’s extent and certainty ratings. We also determined whether each assessment pair was based on similar or dissimilar evidence. Assessment pairs exhibiting disagreement based on the modified crosswalk despite a similar evidence base were qualitatively analyzed to identify reasons for disagreement.

We identified 15 assessment pairs and seven out of fifteen were based on similar evidence. G-BA and ICER assessments disagreed for each of these drugs. For 4/7 drugs, G-BA (but not ICER) determined the evidence was unsuitable for assessment: for 2/4 drugs, G-BA concluded the key trials did not appropriately assess the comparator therapy; for 1/4, G-BA did not accept results of a before-and-after study due to non-comparable study settings; for 1/4, G-BA determined follow-up in the key trial was too short. Among assessment pairs where both organizations assessed the evidence, reasons for disagreement included concerns about long-term safety, generalizability, and study design.

This study underscores the role of value judgments within assessments of clinical effectiveness. These judgments are not always transparently presented in assessment summaries. The lack of clarity regarding these value-based decisions underscores the need for improvements in transparency and communication, which are essential for promoting a more robust health technology assessment process and supporting transferability of assessments across jurisdictions.

Children and young people comprise one quarter of the UK’s population. Neurological trauma (e.g., traumatic brain injury and spinal cord injury) is one of the most common causes of death and disability in this population group, yet health technology innovations for these patients lag behind those for adults.

Using the horizon scanning methodologies developed by the Innovation Observatory, systematic searches were performed to identify registered clinical trials, published funding awards, and news articles that focused on innovative devices and digital and diagnostic health technologies developed for use in children and young people (from 28 days after birth up to and including 18 years of age) with actual or suspected neurological trauma. The search results were screened for relevance, and key information on the included technologies was extracted and summarized.

Twenty-nine technologies were identified, of which 10 were commercially available. The majority were developed in the UK or the USA. Overall, the development pipeline was evenly split amongst technologies considered to be a device (37%), digital (34%), or diagnostic (29%). Most technologies were intended for use across settings by healthcare professionals, either for initial onsite assessment, for in-hospital management, or for rehabilitation in hospital or in the community.

Results from this horizon scan show that development of technologies for pediatric neurological trauma is currently limited, with only a small number of the technologies being developed covering an area of unmet need. To complement the horizon scan, we also sought stakeholder insights on medical technologies for this population group. The combined results and final conclusions will be shared in a future publication.

Technology is central in supporting older people with their daily tasks and independence at home. This project aimed to identify technologies that can be built into residential environments (e.g., appliances, fixtures, or fittings) to support older people in activities of daily living (ADL) through a horizon scan (HS) informed by public insights on unmet needs and priorities.

A survey of members of the public was conducted to prioritize outcomes included within an evidence and gap map (EGM) framework. The EGM aimed to illustrate the current landscape of technologies supporting ADL in residential settings (e.g., care homes) and innovation gaps. The EGM results were shared with end users in a workshop discussion on the current range of technologies aimed at supporting ADL in residential settings. This was facilitated using vignettes to elicit views on unmet needs and priorities for technology development. The workshop informed the scope of the HS to identify and prioritize emerging technologies that could address unmet needs.

This project successfully embedded public involvement throughout to identify innovation gaps in technologies supporting ADL, unmet needs among end users, and potential solutions to these needs. The HS identified 190 technologies that were ready to market. All the technologies had potential to address identified unmet needs and could be built into the residential environment to support older people with ADL and to improve their quality of life, independence, and safety at home. Horizon scanning research can meaningfully involve stakeholders and take direction from their insights to enable voices less often heard to drive innovation in areas where it is needed.

Involving stakeholders in research using evidence synthesis and qualitative methods helps to gain a better understanding of gaps in innovation, the related unmet needs, and the technologies that might address these needs. Public involvement in the survey and workshop influenced the conduct and interpretation of the EGM, the scope of the HS, and the interpretation of the findings.